28 results about "Placental tissue" patented technology

The invention discloses a step-by-step targeting placenta trophoblast micro-nano robot as well as a preparation method and application thereof. The micro-nano robot comprises a yeast cell wall of a bag-shaped structure, bio-enzyme unevenly distributed on the surface of the yeast cell wall and targeted placenta trophoblast drug-loaded nanoparticles located in the yeast cell wall. The surfaces of the targeted placenta trophoblast drug-loaded nanoparticles are connected with placenta-like chondroitin sulfate A binding polypeptides. Inflammation placenta tissue can be targeted through macrophages, the medicine is accurately delivered to placenta trophoblastic cells through the medicine-carrying nano-particles connected with the targeting peptide, step-by-step accurate targeting is achieved, the medicine does not penetrate through the placenta barrier to reach the body of a fetus, and high biological safety is achieved for pregnancy administration.

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located on top of and within the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high levels of laminin-5, a cell adhesion bio-active factor shown to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The present application relates to the technical field of medical data fusion processing, and discloses a method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers, wherein the method comprises: obtaining digital whole field image of placental tissue section and serum biomarker detection data at the same period; constructing a multi-modal sample data set; extracting multi-scale structure features of placental microenvironment; constructing serum biomarker discriminant features; dynamically fusing placental image features and serum marker features; constructing a prediction model for adverse pregnancy outcomes of preeclampsia and outputting a prediction probability. Compared with the prior art which only relies on single image information or single serum biomarker for risk assessment, it is difficult to realize stable prediction of the coordinated changes of placental microenvironment abnormalities and biochemical abnormalities. Due to the multi-scale image structure analysis, the model generalization ability for predicting adverse pregnancy outcomes of preeclampsia is improved.

The present invention relates to a device for simplifying the manual placenta removal procedure, which can be used to locate the placenta in the event that the placenta or the placental fragment remaining in the placenta, which does not spontaneously detach from the uterus after a natural birth, is removed by the manual placenta removal procedure, characterized in that it comprises;an elastic body (1) made of a flexible material, which is placed over the pregnant woman's abdomen immediately after birth, several strip sensors (2) on the surface of the elastic body (1) in contact with the patient's abdomen, which detect the density difference due to the tissue in the placenta, several warning LEDs (3) on the back of the elastic body (1), which, when the placenta is detected by the strip sensors (2), indicate the area corresponding to the placenta by flashing, and a control unit (4) which is connected to the elastic body (1) and controls and regulates the elastic body (1), the strip sensor (2) and the warning LED (3).

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.

Methods for isolating a population of cells from tissue are disclosed herein. In particular, the present disclosure provides methods for isolating cytotrophoblasts from placental tissue. The methods include isolating a population of cells with the use of a laboratory apparatus that is coated with a lubricant, such as petroleum jelly. The methods described herein achieve consistent in vitro isolation of purified cells.

The invention is directed to a composition of soluble placental ECM in storage solution and the methods of manufacture related thereto. The solubilized placental ECM solution is manufactured through a process of partitioning placental ECM from the placental tissue in a high acidic pH environment and performing an ultrafiltration step and diafiltration step through a tangential flow filtration system to increase the pH. The soluble placental ECM retains the native characteristics of placental ECM components and includes collagens (types I, III, V, VI, IX, and X), elastin, laminin, and fibronectin.

The present invention relates to the technical field of lipopolysaccharide preparations, specifically, to a placental lipopolysaccharide preparation and a preparation method thereof, comprising the following components: 90-95 parts by weight of placental tissue, 1-5 parts by weight of sodium carbonate, 0.1-1 parts by weight of trypsin, 0.1-0.5 parts by weight of leupeptin, 1-2 parts by weight of chloroform, 0.1-1 parts by weight of chondroitin sulfate, 5-10 parts by weight of trichloroacetic acid, 70-80 parts by weight of methanol, 0.1-1 parts by weight of ascorbic acid and 0.5-1 parts by weight of sodium chloride. Since leupeptin can inhibit the activity of trypsin, it protects components such as proteins and peptides that have auxiliary effects on immunomodulation from being destroyed, thereby ensuring the quality and efficacy of the final preparation. Adding chondroitin sulfate can form a physical barrier or interact with lipopolysaccharide intermolecularly, thereby reducing the exposure of lipopolysaccharide in a complex chemical environment and preventing it from undergoing structural changes or loss of activity due to changes in the chemical environment.

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.

This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

The present application discloses a method for obtaining maternal-derived mesenchymal stem cells from the placenta. The method for obtaining maternal-derived mesenchymal stem cells from the placenta in the present application includes obtaining placental tissue from a position within a radius of 5 cm from the umbilical cord in the placenta and more than 0.5 cm from the fetal surface; subjecting the placental tissue to enzymatic digestion treatment with an enzymatic digestion solution, and then culturing the product of the enzymatic digestion treatment to obtain maternal-derived mesenchymal stem cells. The method of the present application solves the technical problem of separating maternal-derived mesenchymal stem cells from the placenta. The prepared maternal-derived mesenchymal stem cells are large in quantity, high in purity, and not easily contaminated with neonatal cells, and can meet the clinical application requirements; the method of the present application solves the problems of low quantity of maternal-derived mesenchymal stem cells obtained from the decidua basalis and easy loss of the decidua basalis, and provides a new solution and approach for obtaining maternal-derived mesenchymal stem cells from the placenta.

The application discloses a kind of construction methods of mouse placenta targeted gene interference model and its application.The method comprises the following steps: first, pregnant mouse is anaesthetized and abdominal operation is carried out, and the uterus containing placenta is exposed;Then, the adeno-associated virus carrying gene interference element is directly injected into target placental tissue;Finally, the wound is sutured to complete model construction.The present application overcomes the problem of low virus delivery efficiency caused by maternal-fetal barrier by intraoperative direct site injection, and realizes the efficient and specific gene interference of placental tissue.The model constructed is targeted and precise, has high interference efficiency and low off-target effect, and provides an effective tool for studying placental gene function and pregnancy-related diseases.

A fibrous birth tissue composition fabricated from placental tissue is provided. Methods of processing a mammal's placental tissue to form a fibrous birth tissue composition are provided. Regenerative methods are also provided.

A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The application provides application of a YTHDC1 inhibitor in preparation of a medicine for preventing and treating premature birth, and the medicine takes YTHDC1 gene as a target for placental trophoblasts. The application is based on the fact that the expression level of human YTHDC1 gene in premature placental tissue is significantly higher than that in full-term placenta, a stable overexpression cell strain is constructed aiming at human YTHDC1 gene, and specific siRNA is designed to specifically increase or reduce YTHDC1 expression in human placental trophoblasts, which can correspondingly promote or inhibit the proliferation, apoptosis, migration and invasion ability of the cells. Meanwhile, by injecting in vivo biological preparations interfering with the expression of YTHDC1 gene in an animal model, the expression of YTHDC1 at the placental site can be reduced, the delivery time is prolonged, and the purpose of delaying the occurrence of premature birth is achieved. The application provides a possibility for the development of a clinical premature birth treatment medicine based on YTHDC1 gene, and has great application value and prospect.

To provide a method that treats wrinkles, scarring and other deformities via subdermal injection, and an injectable composition.SOLUTION: The present disclosure provides methods of treating defects such as wrinkles or scars via a subdermal injection of placental tissue components. It also provides placental tissue compositions maintained within the barrel of a syringe. The placental tissue compositions may be for use in treating such defects.SELECTED DRAWING: Figure 1A

The application provides a rat uterine perfusion model and a construction method and application thereof, and belongs to the technical field of animal models. The construction method comprises the following steps: ligating blood vessels at a left kidney of a dead pregnant rat, blood vessels at a bifurcation of the upper end of the left kidney, bifurcation of the upper side and both sides of the internal iliac artery and the internal iliac vein, the right kidney and the bifurcation of the abdominal aorta and the posterior vena cava, and then inserting a tube into the abdominal aorta and the posterior vena cava, and pumping perfusion liquid from the abdominal aorta to obtain the model. The model forms a reproductive artery-placenta-fetus-placenta-reproductive vein circulation, maximally guarantees placental activity, and retains complete placental tissue. The model is simple to prepare and easy to obtain, can more truly and accurately simulate the circulation process of maternal body temperature and complete nutrients in the placenta supplied to the fetus through the mother and the placenta in the whole permeability experiment, and thus more objectively studies the permeability of a compound in the placenta, and is more reliable than a human placental perfusion model.

This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

Provided herein are tissue grafts, and in particular human placenta-derived tissue grafts and methods and articles for the manufacture and use thereof.

Compositions comprising translucent, dehydrated placental tissue and methods of preparing and using those tissues are provided. Repeated dehydration techniques may produce translucent, dehydrated placental tissues, including translucent, dehydrated placental membrane and umbilical cord, with improved visualization and / or handling characteristics. The present invention also includes methods of healing a wound of the skin, eye, nerve, tendon, muscle, dental region, or dura, including burns, comprising applying the translucent, dehydrated placental tissues of the invention to the wound.

Systems and methods for assessing a level of prenatal hypoxia or placenta maturity. The method comprises transmitting ultrasonic waves into an in-vivo placenta, receiving ultrasonic reflections from the placenta, converting the received ultrasonic reflections into electrical signals, computationally determining, from the electrical signals, at least one measure of placenta tissue properties relating to the acoustic interaction of the placenta tissue with the transmitted ultrasonic waves, and determining the level of prenatal hypoxia or placenta maturity based on the at least one measure of the placenta tissue properties.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

A fibrous birth tissue composition fabricated from placental tissue is provided. Methods of processing a mammal's placental tissue to form a fibrous birth tissue composition are provided. Regenerative methods are also provided.